AstraZeneca Opposes MDL In Nexium Bone Density Suits

Law360, Dallas (November 29, 2012, 7:13 PM EST) -- AstraZeneca LP on Thursday asked the U.S. Judicial Panel on Multidistrict Litigation not to consolidate nearly 40 individual cases and putative class actions that allege taking the heartburn drug Nexium causes bone density loss, saying causation issues in the cases are too disparate.

The company said it doesn’t want to consolidate cases in which plaintiffs are alleging different injuries, saying a hip or wrist fracture case doesn’t have enough in common with cases alleging taking Nexium could lead to potential heart problems for combined discovery to...
To view the full article, register now.